Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Marco Villena"'
Autor:
Jule Vasquez, Rossana Ruiz, Karina Aliaga, Fernando Valencia, Marco Villena, Shirley Quintana, Tatiana Vidaurre, Luis Casanova
Publikováno v:
JCO Global Oncology, Vol , Iss 7, Pp 1199-1205 (2021)
PURPOSEMajor progress has occurred in multiple myeloma (MM) treatment in recent years, but this is not seen in low- and middle-income countries.MATERIALS AND METHODSWe retrospectively assessed the efficacy and safety of cyclophosphamide, thalidomide,
Externí odkaz:
https://doaj.org/article/40fe7733e4d94cae8b8d109a8dbb7b18
Autor:
Carlos Santos-Ortiz, Javier Manrique, Edgar Amorín, Gustavo Sarria, Miriam Salazar, Abel Limache, Marco Villena, Jorge Dunstan, Julio Abugattas, Tatiana Vidaurre
Publikováno v:
Revista Peruana de Medicina Experimental y Salud Pública, Vol 33, Iss 3, Pp 535-9 (2016)
Against a backdrop of global equity in cancer prevention and control, the National Institute of Neoplastic Diseases (INEN), a national reference center, has designed and developed innovative strategies and programs with the intent to meet institution
Externí odkaz:
https://doaj.org/article/5d2c95520ffd4e05bc68004bd4ec60cd
Publikováno v:
Interciencia médica. 12:38-46
Describimos el caso de un paciente portador de Desorden Linfoproliferativo Germinotrópico (DLG) Asociado a Virus Epstein Baar (EBV) y herpesvirus 8 (HHV8/KSVH), el primer reporte de esta entidad se realizo en la revista Blood del año 2002 (1) y a l
Autor:
Marco Villena, Tatiana Vidaurre, Shirley Quintana, Fernando Valencia, Karina Aliaga, Luis Casanova, Rossana Ruiz, Jule Vasquez
Publikováno v:
JCO Global Oncology
PURPOSE Major progress has occurred in multiple myeloma (MM) treatment in recent years, but this is not seen in low- and middle-income countries. MATERIALS AND METHODS We retrospectively assessed the efficacy and safety of cyclophosphamide, thalidomi
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 21:S162-S163
Background Peru is a middle-income country with limited options to access to novel therapies in multiple myeloma (MM). Bortezomib has been introduced as salvage treatment a few years ago. In this setting, bortezomib, thalidomide, dexamethasone (VTD)
Autor:
Lizbeth Lachira-Yparraguirre, Daniel J Enriquez, Ali Al-kassab-Córdova, Greenlandia Ferreyros-Brandon, Emperatriz Ortega, Juan C Haro, Luis Malpica Castillo, Sofia Lozano-Ballena, Cesar Samanez-Figari, Shirley Quintana, Juan L Garcia-Leon, Katia Roque, Gustavo Sandival-Ampuero, Marco Villena
Publikováno v:
Blood. 136:28-29
Background: Acute myeloid leukemia (AML) is a highly heterogeneous disease with new cases commonly diagnosed in the elderly population. Despite advances in AML therapy, disease outcomes remain poor. Between 2010 and 2016, the reported 5-year overall
Autor:
Cindy Alcarraz, Daniela Dueñas, Carlos Barrionuevo, Cesar Samanez-Figari, Sandro Casavilca, Ursula Aviles-Perez, Bryan Valcarcel, Gustavo Sandival-Ampuero, Marco Villena, Juan C Haro, Shirley Quintana, Daniel J Enriquez, Luis Malpica Castillo
Publikováno v:
Blood. 136:38-39
Background: Diffuse large B-cell lymphoma (DLBCL) is the most common variant of non-Hodgkin lymphoma (NHL) accounting for approximately 30% of the NHL cases worldwide. Previous reports have associated certain viral infections with the development of
Autor:
Luis Malpica Castillo, Daniel J Enriquez, Marco Villena, Cesar Samanez-Figari, Cindy Alcarraz, Daniela Dueñas, Shirley Quintana, Gustavo Sandival-Ampuero, Sandro Casavilca, Ursula Aviles-Perez, Carlos Barrionuevo, Bryan Valcarcel, Juan C Haro
Publikováno v:
Blood. 136:22-23
Background: The human T-cell lymphotropic virus type 1 (HTLV-1) is an oncogenic retrovirus that affects CD4+ T-cell lymphocytes and is the cause for adult T-cell leukemia/lymphoma (ATLL), an aggressive peripheral T-cell neoplasm. Hodgkin-like ATLL su
Autor:
Edgar Amorin, Jorge Dunstan, Tatiana Vidaurre, Gustavo R. Sarria, Julio Abugattas, Javier Manrique, Marco Villena, Abel Limache, Miriam Salazar, Carlos Santos-Ortiz
Publikováno v:
Revista Peruana de Medicina Experimental y Salud Publica, Volume: 33, Issue: 3, Pages: 535-539, Published: JUL 2016
En el marco de las acciones globales en la prevención y control del cáncer, el Instituto Nacional de Enfermedades Neoplásicas (INEN), centro de referencia nacional, ha diseñado y desarrollado estrategias y programas innovadores que están orienta
Autor:
Lorena Escalante, C. Samanez, Shirley Quintana, Lourdes Lopez, Luis Casanova, Carlos E. Vigil, Marco Villena
Publikováno v:
Journal of Clinical Oncology. 31:7072-7072
7072 Background: Novel intensive chemotherapy regimens impacted in the prognosis of adolescent and young adult pts with ALL. The application of pediatric inspired therapies demonstrated complete response reported to be > 80%, and long-term survival r